ArticleContemporary clinical trials communications2017

Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis.

Anita D'Souza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.